News & Story Ideas
Research for prevention and treatment of infectious diseases is traditionally underfunded by industry and governments until a crisis makes headlines. Dr. Teper discusses the efforts of companies large and small to develop drugs to fight Ebola and other rare infectious diseases.
IMMUNE Pharmaceuticals has several drugs in clinical trials to fight autoimmune diseases such as Crohn’s, Ulcerative Colitis and Inflammatory Bowel Disease. Drs. Teper and Hehenberger discuss treatments that hold hope for those suffering from these chronic diseases.
Drs. Teper and Hehenberger discuss the promise of antibody nanoparticle conjugates (NanomAbs), a combination of drugs for targeting cancers in tissues, cells and at the molecular level. They discuss the next generation of cancer drugs they are developing with the Weizmann Institute of Science’s technology transfer company Yeda.
Shuttling between New York and the Israeli high-tech enclave of Herzliya Pituach, Dr. Teper grew IMMUNE Pharmaceuticals to a NASDAQ listed company in three years. He shares how he harnessed entrepreneurial spirit, innovation, commitment, passion and teamwork to quickly build a thriving new business.
Dr. Hehenberger was diagnosed with type 1 diabetes at an early age and underwent kidney and pancreas transplants. She shares information on the illness and efforts to combat it.
Drs. Teper and Hehenberger discuss symptoms associated with pain caused by damage to peripheral nerves; causes including diabetes, shingles and chemotherapy; and treatments available to ease the pain.
Dr. Hehenberger shares resources available through Lyfebulb, an educational and social platform she founded to help people with chronic illnesses lead optimal lifestyles.
Drawing on their global expertise, Drs. Teper and Hehenberger discuss entrepreneurship, investment opportunities, biotech hubs and Israel’s role as a “startup nation.”
Five of the top ten drugs sold in the world are monoclonal antibodies, and eight monoclonal antibodies have each reached $1B in annual sales. Drs. Teper and Hehenberger discuss these and other investment opportunities in the biopharmaceutical industry.
From his three decades of leadership at global firms, Dr. Teper shares principles of high touch, high energy and high performance management.